Can The BEST-CLI Trial Tell Us Whether Saving A Limb Also Prolongs Survival?

Peter A. Schneider, MD University of California San Francisco

Peter A. Schneider Disclosures

Consulting:


Surmodics, Medtronic, Boston Scientific, Phillips, Cagent, Acotec, Abbott, Endologix, Shockwave, Silk Road, Healthcare Inroads, Inari, BD

Is there a survival benefit to limb salvage?

- One goal of CLTI treatment is amputation prevention.
- When the limb is not salvageable, a secondary goal is to proceed to major amputation expeditiously to prevent systemic infection and assist the patient in becoming as physically functional as possible without the limb.


• The loss of the limb has significant repercussions on the patient's health, mobility, independence, financial status, and almost always impacts the patient's family.


• CLTI management requires the significant expenditure of time, energy and resources by the patient, family, healthcare team, and healthcare system.



CLTI: Long-term Mortality










Age 73yrs 67yrs Tissue loss 88% 80% Tibial disease 100% 67%		BA	SIL-2		BEST CLI Con	ort 1	
Tissue loss 88% 80% Tibial disease 100% 67% Endo technical success 87% 85% Crossover: endo to bypass 19% 23.5% BASIL-2 patients are older, sicker, more tibial disease. BASIL-2 patients are older, sicker, more tibial disease. Statin usage 67-71% 76-80%* Statin usage 70-79% 75-80%	Enrolled participants	34	5		1434		
BEST-CLI BASIL-2 Aspirin usage 67-71% 76-80%	Age	73	rs		67yrs		
Endo technical success 87% 85% Crossover: endo to bypass 19% 23.5% BASIL-2 patients are older, sicker, more tibial disease. BASIL-1 BASIL-2 Aspirin usage 67-71% 76-80%* Statin usage 70-79% 75-80%	Tissue loss	88	%	80%			
BASIL-2 patients are older, sicker, more tibial disease. BEST-CLI BASIL-2 Aspirin usage 67-71% 76-80%* Statin usage 70-79% 75-80%	Tibial disease	100	0%	67%			
BASIL-2 patients are older, sicker, more tibial disease. BEST-CLI BASIL-2 Aspirin usage 67-71% 76-80%* Statin usage 70-79% 75-80%	Endo technical success		%		85%		
BEST-CLI BASIL-2 Aspirin usage 67-71% 76-80%* Statin usage 70-79% 75-80%	Crossover: endo to bypas	s 199	%		23.5%		
Aspirin usage 67-71% 76-80%* Statin usage 70-79% 75-80%	BASIL-2 patients	are older	, sicker, mo	ore tibi	ial disease.		
Aspirin usage 67-71% 76-80%* Statin usage 70-79% 75-80%							
Statin usage 70-79% 75-80%		BEST-	CLI	BA	SIL-2		
	Aspirin usage	67-71%	6	76-8	76-80%*		
Smoking 35-37% 19-22%	Statin usage	70-79%	6	75-80%			
	Smoking	35-379	6	19-22%			




 INDURFECTIONS
 attack
 bit

 of GDMT
 %±SE
 0
 39.6±4.7
 69.2±6.0

 Theor medications
 atrik
 33
 9
 5

 of GDMT
 %±SE
 0
 39.7±10.6
 52.5±11.6



Mortality After Major Amputation

A Meta-analysis of Long-term Mortality and	Table III. Weighted mortality rates						
Associated Risk Factors following Lower	Author	l year	2 years	3 years	5 years	Total	
Extremity Amputation	Abola	-	-	21.8	-	21.8	
	Barnes	24.1	29.8	-	-	29.8	
Stern et al. Ann Vasc Surg 2017;42:322	Carmona	38.3	52.1	-	77.4	86.3	
	Chin	-	-	-	-	18.8	
	Fortington	44	-	-	77	77	
	Hambleton	31	-	-	56	56	
	Heikkinen	43.9	54	-	80.2	80.2	
	Hershkovitz	46.2	-	-	-	46.2	
	Icks	34.8	-	-	64.3	55.2	
	Izumi	-	-	-	-	34.3	
	Jindeel	9.1	-	-	25.6	25.6	
	Jones	48.3	61.4	70.9	-	70.9	
	Jordan	-	-	-	-	75.4	
	Kalbaugh	23.3	37.4	51.9	64.2	64.2	
	Rosen	44	-	-	-	44	
	Scott	35.7	-	-	-	35.7	
	Shah	30	40	-	-	40	
	Sheahan	16.1	-	-	56.5	56.5	
	Stone	53	-	-	77	77	
	Taylor	-	-	-	-	13.6	
	Tseng	21.5	-		59.8	59.8	
	Total (weighted)	48.0	61.3	70.6	62.2	70.1	
	_					_	





Meshkin et al. J Foot an

kle Surg 2021;60:567


Is there a survival benefit to limb salvage?

- Historical therapeutic nihilism in the management of CLTI: asserts that many CLTI presentations are unsalvageable, little can be done, and patients would be better served by primary amputation and rehabilitation rather than complex efforts at limb preservation.
- Our decision-making process would be substantially improved by understanding whether amputation prevention extends life.





Survival Decreased After Amputation



Can The BEST-CLI Trial Tell Us Whether Saving A Limb Also Prolongs Survival? Conclusion

Limb salvage may extend life, but we have only indirect evidence. Our decision-making process would be substantially improved by understanding whether amputation prevention improves survival. No RCT of primary amputation will ever be performed. BEST-CLI patients will be propensity matched to gain insight into the survival question

Can The BEST-CLI Trial Tell Us Whether Saving A Limb Also Prolongs Survival?

> Peter A. Schneider, MD University of California San Francisco